AbbVie Stock Rises Amid Market Decline
AbbVie (ABBV) stock has gained 2.9% over the past five trading days while the S&P 500 fell by 1%. The company recently announced positive Phase 3 results for its cancer therapy epcoritamab and received new FDA approval for SKYRIZI in pediatric patients.
Tickers: $ABBV $BMY $JNJ $LLY $MRK $SPGI
Topics: pharmaceuticals portfolio diversification stock correlation